Angioimmunoblastic T-cell Lymphoma: Clinical Characteristics and Treatment Outcomes.
- Author:
Ji Yeon BAEK
1
;
Sook Ryun PARK
;
In Sil CHOI
;
Sang Il KIM
;
Dong Wan KIM
;
Jee Hyun KIM
;
Sung Soo YOON
;
Seonyang PARK
;
Byoung Kook KIM
;
Noe Kyeong KIM
;
Dae Seog HEO
Author Information
- Publication Type:Original Article
- Keywords: Angioimmunoblastic; T-cell lymphoma; Clinical features; Prognosis; Treatment
- MeSH: Bone Marrow; Drug Therapy; Drug Therapy, Combination; Follow-Up Studies; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell*; Prognosis; Retrospective Studies; Skin; T-Lymphocytes*
- From:Korean Journal of Hematology 2005;40(1):8-14
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: An angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of lymphoma, accounting for only 1 to 2% of studies on non-Hodgkin's lymphomas. Because of the rarity of this disease, most studies have been small, including cases of various T-cell Non-Hodgkin's Lymphoma (T-NHL). Those patients diagnosed as AITL, during the last 8 years at a single institution (Seoul National University Hospital), were retrospectively analyzed to determine the clinical features and treatment outcomes of AITL. METHODS: All 24 of the patients diagnosed with AITL between February 1995 and February 2003 were included in this retrospective review. RESULTS: The predominant characteristics of the population were: median age 62 years (range, 32~81); M/F=18/6; nodal involvement 24/24 (100%); extranodal involvement, particularly bone marrow 16/20 (80%); skin involvement 6/24 (25%); B-symptoms 18/24 (75%) and advanced disease (stages III and IV) in 20/24 (83%). Twenty-three of the 24 patients received combination chemotherapy, with 8/23 (35%) of patients obtaining a CR. The median CR duration was 18.1 months. With a median follow-up of 40.9 months, the 5-year OS rate was 28%, with median survival of 8.7 months. According to a univariate analysis, an elevated LDH showed a tendency to negatively influence the survival. CONCLUSION: The prognosis of AITL is poor compared to other NHL, with a low CR rate and short CR duration and OS. From our data, the CR rate after first- or second-line chemotherapy were low (35%), compared with those previously described in Western reports.
